What is Elucid?
Elucid operates at the intersection of artificial intelligence and cardiovascular health, offering a sophisticated software suite that quantifies atherosclerotic plaque characteristics. Unlike traditional diagnostic methods, Elucid's technology provides a non-invasive alternative that mirrors the accuracy of histopathology, specifically identifying the Lipid Rich Necrotic Core. This capability is essential for physicians aiming to optimize treatment pathways and improve patient outcomes through data-backed precision medicine. By reducing the reliance on invasive procedures, Elucid not only enhances clinical accuracy but also drives significant cost efficiencies within healthcare systems, positioning itself as a high-authority player in the medical technology sector.
How much funding has Elucid raised?
Elucid has raised a total of $207.2M across 3 funding rounds:
Grant
$696K
Series A
$8M
Stock/Share Issuance
$36.5M
Grant (2014): $696K with participation from National Science Foundation
Series A (2021): $8M led by University of Michigan, MedTex Ventures, IAG Capital Partners, Willamette Valley Capital, BlueStone Venture Partners, Checkmate Capital, Angel Physicians Fund, and Global Health Impact Fund
Stock/Share Issuance (2025): $36.5M, investors not publicly disclosed
Key Investors in Elucid
BlueStone Venture Partners
BlueStone Venture Partners is a life sciences venture capital fund that targets innovative companies, particularly those located outside traditional coastal hubs, to foster regional growth and technological advancement.
Checkmate Capital
Checkmate Capital is a management consulting and investment firm that leverages deep advisory expertise to support companies in the biotechnology and energy sectors through disciplined, long-term value creation.
National Science Foundation
The National Science Foundation is an independent federal agency dedicated to promoting the progress of science and advancing national health and prosperity through strategic research grants.
What's next for Elucid?
With the successful closure of this major strategic investment, Elucid is well-positioned to expand its global footprint and deepen its clinical integration. The company's roadmap likely includes scaling its commercial sales force, enhancing its AI diagnostic algorithms through further clinical validation, and pursuing additional regulatory clearances in emerging markets. As the healthcare industry continues to prioritize value-based care, Elucid's ability to provide objective, quantifiable data on plaque morphology will be instrumental in shaping the future of cardiovascular disease management. The firm is now poised to transition from a high-growth innovator to a standard-bearer for AI-enabled diagnostic precision in the enterprise medical market.
See full Elucid company page
